Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on the ED market. But the company is facing some headwind in the country, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med.
Pfizer's new breast-cancer-fighter, Ibrance, has gotten off to a quick start in patients with advanced breast cancer. And now, the company is embarking on a study to see whether it can work earlier in the disease, too.
Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and a national unease about the infection spreading on college campuses. Now, just in time for the back to school season, the New York-based pharma on Friday announced positive late-stage results in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.
Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers--including Evercore ISI analyst Umer Raffat, who polled investors last week. And while there are lots of possibilities floating around, his respondents seem to have a pair of potential deals in mind.
When Pfizer agreed to shell out $15 billion-plus for Hospira earlier this year, the pharma giant added major heft to its biosimilars pipeline. At the time, CEO Ian Read said the two companies had "complementary" portfolios of biosimilar prospects--and his tune hasn't changed since.
Pfizer plans to pay doctors in England to prescribe its drug Lyrica. But don't jump to conclusions. These payments are in a category all their own.
The immuno-oncology arena is seeing a new player enter the hottest game in R&D. And some of the biggest companies in biopharma are pushing into early-stage studies, spawning a fresh rivalry as researchers jockey for the lead position in what promises to be a hotly contested race.
Last year, U.K. officials lambasted Pfizer's proposed takeover of AstraZeneca, and Pfizer has drawn criticism for its hard line on generic Lyrica use. Now, Britain's competition watchdog is accusing the drugmaker of violating U.K. and European laws by jacking up costs for another epilepsy med.
Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $16 billion deal gives Pfizer added heft in injectable generics, not to mention a solid biosimilars pipeline.
So far, the market looks ripe for copies of Teva's multiple sclerosis hit, Copaxone. And Pfizer wants to get in on that.